Dr. Khan holds a PhD in Human Genetics and an MBA. Before founding Serna bio, Dr. Khan was Managing Director of Discovery Sciences at Sensyne Health Plc (now: Arcturis) where she established the scientific strategy, built the data science and discovery teams and led the pharma partnerships with Bayer, BMS, Roche and Alexion and others. She has also held senior roles at BenevolentAI and Meta (acquired by Chan Zuckerberg BioHub). 

 

Born and raised in Pakistan, Dr. Khan has a passion for spearheading diversity in STEM. She was named 50 Movers and Shakers in BioBusiness and 30 Rising Leaders in Biotech 2020

Dr. Incarnato obtained his PhD in molecular biotechnologies from the University of Siena (Italy). He is an expert in RNA structure and computational biology.

 

 In addition to being the CSO at Serna Bio, Dr. Incarnato is leading research in RNA structure at the University of Groningen (the Netherlands). His work has pioneered cutting-edge experimental and computational tools for RNA structure analysis that are now widely adopted both in academia and in industry. His lab solved the first structure of the SARS-CoV-2 RNA genome in living infected host cells, at the beginning of the COVID-19 pandemic.